Navigation Links
Orexigen(R) Therapeutics Prices Public Offering of Common Stock
Date:7/23/2009

SAN DIEGO, July 23 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that it has priced an underwritten public offering of 10,000,000 shares of its common stock at a price of $7.50 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $70.9 million. Orexigen has granted the underwriter a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover overallotments, if any. The offering is expected to close on or about July 28, 2009, subject to satisfaction of customary closing conditions. Leerink Swann LLC is acting as sole book-running manager for the offering. Lazard Capital Markets LLC, Canaccord Adams Inc., JMP Securities LLC and Natixis Bleichroeder Inc. are acting as co-managers for the offering.

The securities described above are being offered by Orexigen pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained, when available, from Leerink Swann LLC , Attention: Syndicate Department, One Federal Street, 37th Fl., Boston, MA 02110 or by calling Leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave(R), has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic(TM), is in the later stages of Phase 2 clinical development, with results expected in the second half of 2009. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found athttp://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
4. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
5. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
6. Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
7. Prime Therapeutics Receives TIPPS Certification
8. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
9. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
10. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
11. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 05, 2016 , ... Qrono Inc. , a specialty ... collaboration with the Australian critical medicine company, Phebra Pty Ltd. , to ... medicines can offer improved therapeutic benefits over oral formulations, including better bioavailability, improved ...
(Date:5/5/2016)... ... , ... Einstein Medical is proud to announce that it has ... commentary at the 2016 ASCRS/ASOA Symposium and Congress, which takes place in New Orleans, ... Refractive Surgery and the American Society of Ophthalmic Administrations will be held at the ...
(Date:5/5/2016)... Francisco, CA (PRWEB) , ... May 05, 2016 , ... This weekend, from Friday, May ... will take on steep California terrain at the first Team Semper Fi Mountain Bike Camp, ... Joining them will be mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... Business Journalists , led by the Wharton School’s most prominent professors, help ... one-day program at the Wharton School’s San Francisco campus will feature Wharton ...
(Date:5/5/2016)... ... May 05, 2016 , ... Derrin Doty Group has ... of Bremerton, Port Orchard and communities west of Seattle. The insurance provider’s caring team ... local girl who died suddenly due to complications from the flu, that they have ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Actinic Keratosis Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Actinic Keratosis epidemiology, Actinic Keratosis market valuations ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK , ... today announced Food and Drug Administration (FDA) approval ... that provides heart failure patients with access to ... also have remote monitoring with daily automatic transmission ... heart rate in response to physiological demands. ...
Breaking Medicine Technology: